HDAC9 and cancer: As therapy resistance is a major hurdle in cancer treatment and is often associated with CSCs and epigenetic control [161], HDAC inhibitors possess the ability to induce differentiation of CSCs from their quiescent state, thereby re-sensitising them to other chemotherapy agents.